United States: Formycon And Celltrion Announce FDA Submission Of ABLAs Seeking Approval To Market Aflibercept Biosimilars - Goodwin Procter LLP
Thursday, 6 July 2023
On June 29 and 30, 2023, respectively, Formycon AG ("Formycon") and Celltrion Inc. ("Celltrion") announced submission to the FDA of aBLAs for their aflibercept biosimilar candidates.
|
||||
You Might Like |
||||
